Fuchs Dystrophy Clinical Trials

Find Fuchs Dystrophy Clinical Trials Near You

Effect of Descemet Membrane Polishing in Fuchs Endothelial Corneal Dystrophy

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Fuchs endothelial corneal dystrophy (FECD) is the leading indication for corneal transplantation worldwide. It is characterized by the accumulation of guttae and progressive loss of corneal endothelial cells, leading to corneal edema and visual impairment. Endothelial keratoplasty remains the standard treatment; however, graft shortages have driven the development of cell-based therapies involving the injection of cultured endothelial cells. A key unresolved issue is whether removal of the pathological endothelium prior to injection improves cell adhesion. Clinical data are limited and sometimes contradictory, particularly regarding endothelial polishing. The actual effectiveness of this procedure in removing guttae and enhancing the survival of injected cells remains uncertain. Therefore, an in vivo clinical evaluation is required to assess its impact on guttae removal.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patient affiliated with or entitled to a social security scheme

• Patient scheduled for endothelial keratoplasty for Fuchs endothelial corneal dystrophy

• Patient having received full information and having provided written informed consent

Locations
Other Locations
France
Hopital de Mercy
NOT_YET_RECRUITING
Metz
Cochin Hospital
NOT_YET_RECRUITING
Paris
Hôpital Fondation Rothschild
NOT_YET_RECRUITING
Paris
Centre Hospitalier Universitaire de Rouen
NOT_YET_RECRUITING
Rouen
CHU de Saint-Etienne
RECRUITING
Saint-etienne
Contact Information
Primary
Gilles THURET, MD PhD
gilles.thuret@univ-st-etienne.fr
(0)4 77 12 77 96
Backup
Clara Pfenninger, PhD
clara.pfenninger@chu-st-etienne.fr
(0)4 77 12 02 87
Time Frame
Start Date: 2026-05-21
Estimated Completion Date: 2027-03-01
Participants
Target number of participants: 20
Treatments
Experimental: Experimental Group
Sponsors
Leads: Centre Hospitalier Universitaire de Saint Etienne

This content was sourced from clinicaltrials.gov